The US FDA approved Moderna's mFLUSIVA, the first mRNA-based flu vaccine, on August 5. It is authorized for adults 50-64, with accelerated approval for those 65+. The approval came after an initial rejection, and the vaccine is expected to be available for the 2026-27 season.
FDA approves first mRNA flu vaccine after rare reversal
Source: The Print